Cefiderocol: Clinical Trials

3 trials of Cefiderocol, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 1 not yet recruiting. 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 33Completed 2, Not yet recruiting 1

Follow Cefiderocol: new trials by email Literature Review of Cefiderocol trials Research Report on Cefiderocol

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Targeted Versus Standard Peri-operative Antibiotic Prophylaxis in Patients Colonized With Carbapenemase Producing Enterobacterales Undergoing Liver Transplantation
Ceftazidime - Avibactam ( CAZ-AVI), Meropenem-Vaborbactam, Imipenem+Relebactam - Liver Transplant, Carbapenem-resistant Enterobacterales
Phase 3Not yet recruitingIRCCS Azienda Ospedaliero-Universitaria di Bologna1682026-10-012026-08-12
Clinical Study of Cefiderocol (S-649266) for the Treatment of Nosocomial Pneumonia Caused by Gram-negative Pathogens
Cefiderocol, Meropenem, Linezolid - Healthcare-associated Pneumonia (HCAP), Hospital Acquired Pneumonia (HAP)
Phase 3CompletedShionogi3002017-10-242020-11-13
Study of Cefiderocol (S-649266) or Best Available Therapy for the Treatment of Severe Infections Caused by Carbapenem-resistant Gram-negative Pathogens
Cefiderocol, Best Available Therapy - Healthcare-associated Pneumonia (HCAP), Bloodstream Infections (BSI)
Phase 3CompletedShionogi1522016-09-072021-01-12

Conditions studied

Healthcare-Associated Pneumonia (2)  ·  Pneumonia, Ventilator-Associated (2)  ·  Pneumonia (1)  ·  Sepsis (1)

Sponsors

Shionogi (2)  ·  IRCCS Azienda Ospedaliero-Universitaria di Bologna (1)

Countries

France (2)  ·  Germany (2)  ·  Israel (2)  ·  Italy (2)  ·  Japan (2)  ·  Spain (2)  ·  Taiwan (2)  ·  United States (2)  ·  Belgium (1)  ·  Brazil (1)  ·  Canada (1)  ·  Croatia (1)  ·  Czechia (1)  ·  Estonia (1)  ·  Georgia (1)

Top investigators

Maddalena Giannella, MD, PhD (1)

Results publications

PMID 34792787, PMID 35076335, PMID 31819544, PMID 33058795, PMID 33058798, PMID 33393598, PMID 35025025

NIH funding

2015 (1), 2016 (1), 2025 (1)